UCB (OTCMKTS:UCBJF) Stock Price Down 7.4% – Should You Sell?

Shares of UCB SA (OTCMKTS:UCBJF) dropped 7.4% during trading on Tuesday . The company traded as low as $281.11 and last traded at $297.1875. Approximately 133 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 765 shares. The stock had previously closed at $321.05.

Analysts Set New Price Targets

UCBJF has been the subject of a number of recent analyst reports. Wolfe Research initiated coverage on shares of UCB in a research note on Monday, February 23rd. They issued an “outperform” rating for the company. The Goldman Sachs Group reiterated a “buy” rating on shares of UCB in a research note on Monday, February 16th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy”.

UCB Stock Down 4.2%

The business’s 50 day simple moving average is $295.52 and its 200 day simple moving average is $299.47. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.